osteoporosis

R-spondin 1 promotes vibration-induced bone formation in mouse models of osteoporosis

Authors

Haitao Wang, Tracy A. Brennan, Elizabeth Russell, Jung-Hoon Kim, Kevin P. Egan, Qijun Chen, Craig Israelite, David C. Schultz, Frederick B. Johnson, Robert J. Pignolo

Abstract

Bone tissue adapts to its functional environment by optimizing its morphology for mechanical demand. Among the mechanosensitive cells that recognize and respond to forces in the skeleton are osteocytes, osteoblasts, and mesenchymal progenitor cells (MPCs). Therefore, the ability to use mechanical signals to improve bone health through exercise and devices that deliver mechanical signals is an attractive approach to age-related bone loss; however, the extracellular or circulating mediators of such signals are largely unknown. Using SDS-PAGE separation of proteins secreted by MPCs in response to low-magnitude mechanical signals and in-gel trypsin digestion followed by HPLC and mass spectroscopy, we identified secreted proteins up-regulated by vibratory stimulation. We exploited a cell senescence-associated secretory phenotype screen and reasoned that a subset of vibration-induced proteins with diminished secretion by senescent MPCs will have the capacity to promote bone formation in vivo. We identified one such vibration-induced bone-enhancing (vibe) gene as R-spondin 1, a Wnt pathway modulator, and demonstrated that it has the capacity to promote bone formation in three mouse models of age-related bone loss. By virtue of their secretory status, some vibe proteins may be candidates for pre-clinical development as anabolic agents for the treatment of osteoporosis.

Link to Article

http://dx.doi.org/10.1007/s00109-013-1068-3

Bone loss prevention in ovariectomized rats using stable amorphous calcium carbonate

Authors

Galit Shaltiel, Elad Bar-David, Oren E. Meiron, Eitan Waltman, Assaf Shechter, Eliahu D. Aflalo, David Stepensky, Amir Berman, Berdine R. Martin, Connie M. Weaver, Amir Sagi

Abstract

In assessing the relationship between calcium supplementation and maintaining bone mass or reducing the risk of fracture, the effectiveness of calcium supplementation has never been decisive. Freshwater crayfish rely on amorphous calcium carbonate (ACC), an instable polymorph of calcium carbonate, as the main mineral in the exoskeleton and in the temporary storage organ, the gastrolith. Inspired by the crayfish model, we have previously shown an increase in calcium bioavailability in rats administered with synthetic stable ACC vs. crystalline calcium carbonate (CCC). The current study compared the effects of amorphous calcium derived from either gastrolith or synthetic ACC with those of crystalline calcium, found in commercial CCC or calciumcitrate supplements, in a bone loss prevention model. Rats were subjected to either sham or ovariectomy (OVX) operation (n~20/ group) followed by administration of food pellets supplemented with 0.5% calcium from either source over 12 weeks. Micro-computed tomography (μCT) and histomorphometric analyses revealed bone loss prevention by both gastrolith and ACC treatments, manifested by an increase in morphometric bone parameters, compared to both CCC- and calcium citrate-treated groups. Both gastrolith and ACC treatments resulted in bone formation in the tibia cancellous bone, indicated by dynamic histomorphometry parameters, compared to either the CCC or calcium citrate treatments. Levels of urine deoxypyridinoline (DPD), suggested an anti-resorptive effect of ACC, which was also the only treatment that led to a significant increase in vertebral mechanical strength, as supported by μCT analysis of topology and orientation parameters of the vertebral trabeculae. To our knowledge, such levels of bone loss prevention by calcium supplements have never been reported. These findings thus suggest the potential of both natural (crayfish gastrolith) and, to a greater extent, synthetic ACC sources for the prevention of metabolic bone disorders and possibly of osteoporotic processes.

Link to Article

http://dx.doi.org/10.4236/health.2013.57A2003

The Interleukin 8 Expression and its Possible Relationship with Degenerated and Injured Human Intervertebral Discs

Authors

Basit Saleem Qazi, Tang Kai and Asma Saleem Qazi

Abstract

Purpose: Cervical and Lumbar degenerative disc diseases (DDD) are a common disease of advanced age characterized by progressive changes in the intervertebral disc and associated structures. There have been great efforts for years to explain its pathophysiological mechanism(s). This study aims to provide the expression of IL-8 in a population of patients with lumbar disc herniation, cervical stenosis and vertebral fracture. Material and methods: We compared the level of IL-8 expression in the non-degenerated and degenerated intervertebral disc samples obtained from patients who underwent surgery for vertebral fracture (non degenerated disc), lumbar disc herniation and cervical stenosis (degenerated disc), whose clinical and radiological features were suggestive of disc degeneration. IL-8 expression was studied by using the western blot, immunohistochemistry and enzyme linked immune absorbent assay methods. This study includes comparison of IL-8 concentration in groups based on patient’s age and diagnosis. Results: Significantly higher levels of IL-8 expressions were found in patient with advance age, more in vertebral fracture as compared to lumbar disc herniation and cervical stenosis patients. Conclusion: The findings suggest that both local inflammatory responses occur in lumbar disc herniation, cervical stenosis and vertebral fracture patients. Using specific cytokines either by local or systemic application may reverse the degenerative process.

Link to Article

http://dx.doi.org/10.4172/2165-7939.1000135

Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

Authors

Susan Y. Smith, Nancy Doyle, Marilyne Boyer, Luc Chouinard, Hitoshi Saito

Abstract

Vitamin D insufficiency is common in elderly people worldwide, and intake of supplementary calcium and vitamin D is recommended to those with a high risk of fracture. Several clinical studies and meta-analyses have shown that calcium and vitamin D supplementation reduces osteoporotic fractures, and a strong correlation exists between vitamin D status and fracture risk. Vitamin D supplementations improve calcium balance in the body; however, it remains unclear whether vitamin D directly affects bone metabolism. Recently, eldecalcitol (ELD), an active form of vitamin D analog, has been approved for the treatment of osteoporosis in Japan. A 3-year clinical trial showed ELD treatment increased lumbar spine bone mineral density (BMD) and reduced fracture risk in patients with osteoporosis. To evaluate the mechanism of ELD action in bone remodeling, ovariectomized cynomolgus monkeys were treated with 0.1 or 0.3 μg/day of ELD for 6 months. This treatment increased lumbar BMD by 4.4% and 10.2%, respectively, and suppressed ovariectomy-induced increases in bone turnover markers compared to OVX-vehicle control. Histomorphometric analysis of bone revealed that both bone formation parameters and bone resorption parameters in the trabecular bone of the lumbar vertebrae were suppressed by ELD treatment. ELD treatment also improved biomechanical properties of the lumbar vertebrae and the femoral neck in the ovariectomized cynomolgus monkeys. These results indicate that, in a bone-remodeling animal model, ELD increases BMD and improves bone biomechanical properties by normalizing bone turnover. Therefore, ELD has a direct and potentially beneficial effect on bone metabolism.

Link to Article

http://dx.doi.org/10.1016/j.bone.2013.06.005

Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness

Authors

Tianyi D. Luo and Matthew R. Allen

Abstract

Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL + DEX. Zoledronic acid (0.06 mg/kg) was given monthly via IV infusion for 9 months. DEX (5 mg) was administered daily for one week during each of the last three months of the 9 month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n=3-6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX+ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3-point bending tests, compared to all other treatment groups while the toughness in ZOL+DEX animals was identical to those of untreated controls. These findings suggest not only that short-courses of dexamethasone do not adversely affect toughness in the setting of bisphosphonates, they actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue-level effect could lead to novels approaches for reducing the risk of atypical femoral fractures.

Link to Article

http://www.iupui.edu/~bonelab/BONE-accepted%20version.pdf

Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model

Authors

Steven D. Rhodes, Xiaohua Wu, Yongzheng He, Shi Chen, Hao Yang, Karl W. Staser, Jiapeng Wang, Ping Zhang, Chang Jiang, Hiroki Yokota, Ruizhi Dong, Xianghong Peng, Xianlin Yang, Sreemala Murthy, Mohamad Azhar, Khalid S. Mohammad, Mingjiang Xu, Theresa A. Guise, Feng-Chun Yang

Abstract

Dysregulated TGF-β signaling is associated with a spectrum of osseous defects as seen in Loeys-Dietz syndrome, Marfan syndrome, and Camurati-Engelmann disease. Intriguingly, neurofibromatosis type 1 (NF1) patients exhibit many of these characteristic skeletal features including kyphoscoliosis, osteoporosis, tibial dysplasia, and pseudarthrosis; however, the molecular mechanisms mediating these phenotypes remain unclear. Here, we provide genetic and pharmacologic evidence that hyperactive TGF-β1 signaling pivotally underpins osseous defects in Nf1flox/-;Col2.3Cre mice, a model which closely recapitulates the skeletal abnormalities found in the human disease. Compared to controls, we show that serum TGF-β1 levels are 5–6 fold increased both in Nf1flox/-;Col2.3Cre mice and in a cohort of NF1 patients. Nf1 deficient osteoblasts, the principal source of TGF-β1 in bone, overexpress TGF-β1 in a gene dosage dependent fashion. Moreover, Nf1 deficient osteoblasts and osteoclasts are hyperresponsive to TGF-β1 stimulation, potentiating osteoclast bone resorptive activity while inhibiting osteoblast differentiation. These cellular phenotypes are further accompanied by p21-Ras dependent hyperactivation of the canonical TGF-β1-Smad pathway. Re-expression of the human, full-length neurofibromin GTPase-activating protein (GAP) related domain (NF1 GRD) in primary Nf1 deficient osteoblast progenitors, attenuated TGF-β1 expression levels and reduced Smad phosphorylation in response to TGF-β1 stimulation. As an in vivo proof of principle, we demonstrate that administration of the TβRI kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture non-union in Nf1flox/-;Col2.3Cre mice. In sum, these data demonstrate a pivotal role for hyperactive TGF-β1 signaling in the pathogenesis of NF1 associated osteoporosis and pseudarthrosis, thus implicating the TGF-β signaling pathway as a potential therapeutic target in the treatment of NF1 osseous defects which are refractory to current therapies.

Link to Article

http://dx.doi.org/10.1002/jbmr.1992